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Abstract
Background: Currently, feasible medical treatments are hitherto not satisfying to relieve pSS symptoms, which
concerns numbers of clinical doctors. Acupuncture seems to be an alternative to treat pSS and conduces to good
symptomatic results. However further research is necessary. This trial is to investigate the efficacy of acupuncture on
improving the key symptoms of pSS, which are dryness, pain and fatigue (DPF).
Methods & Design: The study is designed as a randomized controlled trial of two arms with a single centre. We
compare acupuncture with sham acupuncture on symptomatic improvements of pSS. A total of 120 pSS patients,
aged at least 18, with DPF, will be randomly assigned to acupuncture or sham acupuncture groups, where they will
have needle intervention for 8 weeks with 16 weeks of follow-up. Subjects will be assessed each time before
interventions during the 8-week intervention, in week 8 after all interventions and in week 12, 16, 20 and 24 for
follow-up with different measurements. The primary outcome are the proportions of subjects that have 30% or
greater reduction in at least 2 out of 3 items of DPF in Numeric Analog Scale (NAS) scores (0 = the best, 10 = the
severest), calculated between the baseline and the average scores of week 2 to 8. The secondary outcome are
related to individual items of NAS scores, EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI), EULAR
Sjögren’s Syndrome Disease Activity Index (ESSDAI), Schirmer test score and unstimulated salivary flow, serum
Immunoglobulin G, A and M levels, Medical Outcome Study Short Form 36 Short-Form Health Survey (SF-36),
Salivary glands ultrasounds, Hospital Anxiety and Depression (HAD) scale score. The secondary outcome scores are
to be collected at baseline, in week 8, 16, and 24. Besides, individual items of NAS will also be collected in week 12
and 20. Moreover, subjects’ satisfaction and the proportion of the subjects who identified their allocation will also
be measured and analyzed.
Discussion: This study will be the first randomized and controlled pilot trial of acupuncture on alleviating the
symptoms of pSS with relatively long-term follow-up. The result of the study might offer a new option to treat pSS
and might be a clinical proof that acupuncture has beneficial effects on pSS.
Trial registration: ClinicalTrials.gov: NCT02691377 (February 20, 2016)
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Background
Primary Sjögren’s syndrome (pSS) is a systematic auto-
immune disease characterized by high lymphocytic infil-
tration in the exocrine glands such as salivary and
lacrimal gland. The incidence in different populations
varies from 0.5 to 2% [1]. There is a variety of clinical
manifestations in pSS [2], in which, dryness, pain and fa-
tigue (DPF) are considered as the 3 most urgent symp-
toms, and they affect patients quite much [3].
Current available medical treatments for pSS may lead to
either serious adverse side effects, or failure to relieve symp-
toms. Thus, Bio-agents (e.g. rituximab, abatacept, beli-
mumab), immunosuppression (e.g. and azathioprine,
cyclophosphamide, mycophenolate mofetil) or corticoste-
roids should be cautiously applied clinically because of their
safety and cost-effectiveness, although life-threatening com-
plications after taking them are rarely seen. Even the most
frequently prescribed medicine for pSS [4, 5], hydroxychloro-
quine, does not alleviate symptoms compared to the sham in
a recent research [6]. Thus, some patients resort to comple-
mentary and alternative medicine, for example, acupuncture.
Acupuncture, as a non-pharmacologic therapy from
Traditional Chinese Medicine, has been applied in a var-
iety of disorders, including clinical symptoms of dryness
[7]. Researches done in the past have shown the re-
searchers’ recognition and expectation on acupuncture
for dryness, and a research blank in “Acupuncture +
Sjögren’s syndrome” as well [8, 9].
It seems that pSS patients have a good clinical re-
sponse to acupuncture therapy in daily clinical practice,
with acupoints and manipulations inherited from Profes-
sor Lu Zhizheng [10], one of the National Masters of
Traditional Chinese Medicine (no more than 10 people
in China), who has contributed himself to treating and
studying rheumatoid diseases by using herbs and acu-
puncture for over 50 years. Our previous research indi-
cates that acupuncture performs in a synergy with a
particular formula of herbs, with which patients relieve
from dryness of mouths and eyes, pain and fatigue, and
it improves the quality of lives of pSS patients (it’s a re-
sult from our recent study not long after finished, which
has been accepted by a journal but hasn’t been published
yet). However, there are still questions not settled yet,
such as how indeed is the effect of acupuncture on re-
lieving symptoms of pSS statistically; if acupuncture
works, what kind of patients will be benefit from it; and
if not, why do some of the patients think they have
symptomatic improvement after acupuncture. This study
is designed to answer these questions.
Methods & Design
Study design
The study is a single-centre, double blinding and 24-
week randomized and controlled trial with two arms, in
one of which, needles will be inserted into previously set
acupoints while sham acupuncture for the other group.
120 patients with symptomatic pSS are randomly
assigned to acupuncture or sham acupuncture groups in
1:1 ratio. Needles are administered 3 times a week for
the first 4 weeks, twice a week for the second 4 weeks,
with 16-week of follow-up. All the allocation, interven-
tion, randomization and analysis, etc., will be conducted
in Guang’anmen (GAM) Hospital. The primary outcome
is the two proportions of subjects in the two groups that
have 30% or greater reductions in NAS scores in at least
2 out of the 3 DPF items [6]. They are calculated be-
tween baseline and the average scores between week 2
and week 8. The secondary outcome are related to indi-
vidual items of NAS score at baseline, 3 times a week in
week 0 to 8, and once a week at week 12, 16, 20, and 24,
with EULAR Sjögren’s Syndrome Patient Reported Index
(ESSPRI), EULAR Sjögren’s Syndrome Disease Activity
Index (ESSDAI), Schirmer Test Score and Unstimulated
Salivary Flow, Medical Outcome Study Short Form 36
Short-Form Health Survey (SF-36), Salivary glands ultra-
sounds, Hospital Anxiety and Depression (HAD) scale
score, at baseline, week 8, 16 and 24. During the 8-week
intervention, data of the last 24 h is collected each time
before the intervention. Since there are only twice a
week in week 4 to 8 for intervention but 3 times for
NAS collection, the extra one is collected by phone.
Randomization and blinding
Subjects eligible for participation will be randomly
assigned to one of the following study groups, using the
randomization software SAS (Statistical Analysis System)
9.2.
 penetrating acupuncture: 60 subjects
 sham acupuncture: 60 subjects
The statisticians will randomize assignments using a
sequence of number randomly generated by the SAS
(Statistical Analysis System) 9.2, done by a third
organization, a Statistical Department of State Standard-
ized Traditional Chinese Medicine Pharmacology Clinic
(SDSSTCMPC) granted by State Food and Drug Admin-
istration (SFDA). The sequence will be recorded and can
be displayed when necessary. These assignments will be
sent to a study member, who will put them into sealed,
opaque envelopes with dates and signature labels over
the seals. And this study member will not take part in
any of patient interviews, acupuncture intervention, data
collection, or statistical analysis.
Before eligible subjects are randomized into different
groups, informed consent contract will be obtained from
each participant and they will be interviewed to ensure
their baseline data recorded. Then they will allocate and
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come to see the acupuncturist who will open the con-
secutive randomization envelope, and then apply acu-
puncture or sham one according to the assignment
without informing the subjects of their assignments. As
the only one knowing the group assignments of subjects,
the acupuncturist will not participate in any of the inter-
viewing, data collection, or statistical analysis. Every time
before the intervention, except the first time, which is
baseline, the subjects will come to the interviewing room
where the case report form (CRF) with NAS scores will
be filled with their feedback on NAS scores about last
24 h instead of a time point. After the intervention, the
schedule for their acupuncture and interviewing for next




 To meet the American-European Consensus Group
Criteria for primary Sjögren syndrome [11]
 Symptoms have been appearing for less than 5 years;
signed a written informed consent form
 Without taking pSS medicines, or have not been
taking pSS medicines for at least 4 weeks before the
recruitment, or have been taking the same kinds and
doses of pSS medicines (non-steroidalanti-
inflammatory drugs, NSAIDs; oral taken cortical
hormone; pilocarpine; artificial eye liquid; herbal
decoctions) for more than 4 weeks before the
recruitment, or have been taking the same kinds and
doses of other pSS medicines (tripterygium wilfordii;
methotrexate; cyclophosphamide; cyclosporin;
azathioprine; hydroxychloroquine sulfate) for more
than 6 months before the recruitment.
Exclusion criteria
 Secondary Sjogren syndrome
 Have been having serious systemic disorders
recently (lymphoma; central nervous system, renal,
or pulmonary involvement; myositis; or vasculitis) or
severe renal or liver failure
 Have had acupuncture treatments in last 20 days
 With acupuncture contraindications (allergy to
metals, skin lesions on relative acupoints, etc.)
 Subjects who participate in any other clinical trials
in last 30 days before recruitment
 Currently or planning to be pregnant, or at risk of
being pregnant without contraception
 Subjects with a physical or psychological problem,
which may confound the trial results, interfere with
other subject’s participation, or may make it risky to
follow the investigators’ requirements
 Subjects known for or persistent in drug or alcohol
abuses
Recruitment strategies
Patients will be recruited through a number of advertis-
ing strategies, with the information of physicians and the
details and requirements of the trial. Posters in GAM
Hospital, and advertisements on the online official med-
ical medias, such as websites, Weibo (similar to twitter
in China), and Wechat (similar to Facebook in China) of
Rheumatology Department of GAM Hospital, will also
be applied for recruitment. Also, another main recruiting
way is that patients comes from outpatient service.
Intervention
Since sham control is a useful method for determining
the effectiveness of a therapy, we will choose a sham
needle [12] that has a blunt tip and achieves no skin
penetration. To apply the sham needles produces a good
subject blinding effect, the reason of which is that they
have a similar appearance to conventional acupuncture
needles, however, without skin penetration. Also, we put
plastic pads on the acupoints before to cover the areas
so as to keep the patients blinded to if or not there’s
penetration.
Description of sham acupuncture
The sham needle is 0.30mm wide and 25mm long. It
consists of an adhesive pad with a blunt tip (Fig. 1). The
adhesive pad is made of a sterile cylindrical polyethylene
foam (diameter 10mm and height 5mm) with a double-
sided adhesive tape at the bottom. The adhesive pad has
2 functions: one is holding the sham needle on the acu-
points when used in sham acupuncture and the other
function is assisting the implementation of blinding
when used in both sham and real acupuncture. In all,
the only difference between normal and sham needles is
that the sham ones tips are not tapering.
Fig. 1 The sham and real acupuncture we use in this study. a: sham
acupuncture as control; b: real acupuncture. 1. needle handle; 2.
needle body; 3. adhesive pad; 4. blunt tip; 5. Cutis
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Process of the intervention
All of the subjects will be told that we are going to
evaluate the effects of “a new kind of acupuncture”
researching on “deep penetrating needles and shallow
penetrating needles” on pSS, without mentioning sham,
pseudo or the penetration status. The experienced acu-
puncturist will be trained on the sham needles and will
apply both the sham and real needles throughout the
whole trial. Each time before the intervention, subjects
will be asked to meet the interviewer in another room to
provide their answers on CRF with the feelings of the
last 24 h before the intervention, excluding the first
intervention, whose data will be the baseline. Acupoints
and manipulations are the same in 2 groups (Fig. 2),
with bilateral Waiguan (SJ5) with reducing method; bi-
lateral Zhaohai (KI6) with reinforcing method; Cheng-
jiang (RN24), Lianquan (RN23), bilateral Taiyang (EX-
HN5), bilateral Cuanzhu (BL2), bilateral Sizhukong
(SJ23), and bilateral Jiache(ST6) with even method. Dur-
ing the manipulations, twirling, lifting, and thrusting to
elicit Deqi or needle sensation (a composite of unique
sensations interpreted as the flow of qi induced by acu-
puncture and essential for clinical efficacy [13]), will be
applied, and the needles will be remained for 20 min.
Subjects will receive acupuncture or sham acupuncture
3 times a week for the first 4 weeks, twice a week for the
second 4 weeks, followed by 16 weeks of observation
without treatments. For week 4 to 8, intervention will
only be conducted twice a week, therefore one more
interview for NAS scores every week will be on the
phone.
Primary outcome
The numeric analog scale (NAS) [14] scores of DPF (0 =
the best, 10 = the severest) will be measured at the base-
line, three times a week in week 1 to 8, and once a week
in week 12, 16, 20, and 24. By the comparison of the
average scores of week 2 to 8 with those of the baseline
of the two arms, the proportions of the subjects in two
groups that have 30% or greater reductions in NAS
scores in at least 2 out of 3 DPF items, will be the pri-
mary outcome.
Subjects will be asked to provide every NAS score
based on the overall situation of the past 24 h [15] rather
than a point of time. And we will collect NAS scores 3
times a week in week 1 to 8 (24 times in total).
The mentioned outcome measurements will be
assessed at the marked time points respectively (Fig. 3).
Secondary outcome
Secondary outcomes include each items of NAS scores
from week 0 to 8. These items will be measured indi-
vidually at baseline, 3 times a week in week 1 to 8, once
a week in week 12, 16, 20, 24. The secondary outcomes
also include:
 EULAR Sjögren’s Syndrome Patient Reported Index
(ESSPRI) [16] is a very simple index completed by
patients to measure symptoms in pSS. With good
construction validity, it is used as an outcome
measure in clinical trials. There is a 0–10 numerical
scale for each of the four domains, dryness,
discomfort (including pain), global fatigue and
mental fatigue, which are gathered to form the
ESSPRI. For sicca features, six components were
identified, which are ocular, oral, skin, nasal, tracheal
and vaginal.
 EULAR Sjögren’s Syndrome Disease Activity Index
(ESSDAI) [17, 18] is a clinical index completed by
physicians to measure disease activity in patients
with pSS. There are 12 organ-specific ‘domains’ con-
tributing to disease activity. For each domain, fea-
tures of disease activity are classified into three or
four levels according to their severity.
 Schirmer test score and unstimulated salivary flow
[19]: these two tests are the objective reflection to
the lacrimal gland and salivary glands, the results of
which can be greatly impacted by the operator.
Thus, there will be a technician performing these
two tests during the whole trial to maintain the
homogeneity of the operation.
 Serum Immunoglobulin G, A, M levels [20]:
Immunoglobulin G (IgG) is commonly believed in
clinic a reflection of pSS symptom activities and a
study shows weak associations between increasing
fatigue and serum IgG, and the pro-inflammatory
cytokine interleukin-17 (IL-17), were observed.
 Medical Outcome Study Short Form 36 Short-Form
Health Survey (SF-36) [21, 22] is a self-administered
questionnaire with 36 items, which assesses the con-
cepts of physical function, role limitations due to
physical problems, social function, body pain,
Fig. 2 The acupoints we picked in this study and their indications
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general mental health, role limitations due to emo-
tional problems, vitality, and general health percep-
tions. Note that both physical and mental
component summaries can be combined. Scores
range from 0 to 100, with higher scores indicating
better health status [23].
 Salivary glands ultrasounds [24]: image of salivary
glands structures. This can be quantified by a form
based on different features.
 Hospital Anxiety and Depression (HAD) scale score
[25]: A self-assessment scale which has been devel-
oped and found as a reliable instrument for detect-
ing states of depression and anxiety in the setting of
an hospital medical outpatient clinic.
For the secondary outcomes listed above, the measure-
ments are conducted at baseline, in week 8, 16 and 24.
Besides, the satisfaction of patients in two groups and
the proportion of the subjects who identified their allo-
cation will be measured in week 8.
Additionally, we will assess the patients’ satisfaction in
week 24 by two questions. 1) “Would you like to come
for more treatments or recommend it to your friends/
relatives if they have similar symptoms?” The answer will
be either “yes” or “no”. 2) "What is your feeling for the
series of treatment?” The answers will include “excel-
lent”, “good”, “satisfactory”, “It’s okay” and “poor”. The
difference in satisfaction between two groups will be
analyzed.
To evaluate the success rate of blinding, we will ask
subjects in week 8 “how deep do you think the needles
went into your skin?” The answer will be “deep”, “shal-
low” or “no penetration”. The subjects in the two groups
whose answers are either “deep” or “shallow” will be
considered to be blinded successfully, while “no
penetration” unsuccessfully, and the proportions of them
are going to be compared.
Sample size
Sample size will be decided by the primary outcome. Ac-
cording to our unpublished pilot study and literature re-
view [6], the proportions of patients with a more than
30% improvement in NAS scores in at least 2 out of 3
DPF items for acupuncture and placebo is 45% and
17.9% respectively. We use the proportion for placebo
instead of the one in sham acupuncture group, because
no data are available for sham acupuncture so far. A
sample size of 52 for each group will be sufficient to de-
tect a 2% null difference in proportion, with a two-sided
5% level of significance, and a power of 80%. The num-
ber of subjects is increased to 60 in each group (total of
120) when a drop-out rate of 15% is taken into
consideration.
Statistical analysis
For data analysis, statisticians and investigators will be
blinded for the patients’ allocation. Statistical analysis
will be performed using SPSS Ver.20 (SPSS Inc., Chi-
cago, IL, USA) software. Enumeration data will be de-
scribed as frequency and composition ratio. Continuous
data will be presented by Mean ± Standard Deviation
(M ± SD) if they meet normal distribution, otherwise
they will be expressed as Medians ± Interquartile Range
(M ± IQR). Categorical data will be presented by fre-
quency and percentage. The analyses of efficacy will be
based on the intention-to-treat (ITT) analysis set, which
was defined as patients who receive at least one treat-
ment. Missing data for the primary outcome will be
treated by multiple imputation under chained equation,
with m = 50 imputations. The covariates used to
Fig. 3 Trial flow & study design. General information = age, sex, weight, time when symptoms emerge, time when diagnosed, anti-SSA antibodies, abnormal
Schirmer test results, decreased unstimulated salivary flow, previous systemic involvement, previous treatment with another immunosuppressant, current sys-
temic involvement. 1st outcome=numeric analog scale (NAS) (Dryness, Pain and Fatigue). 2nd outcome= EULAR Sjogren Syndrome Patient Reported Index
(ESSPRI), EULAR Sjogren Syndrome Disease Activity Index (ESSDAI), Medical Outcome Study Short From 36 Short-Form Health Survey (SF-36), Hospital Anxiety
and Depression (HAD), Serum Immunoglobulin (IgG), IgA and IgM, Schirner test score and unstimulated salivary flow, salivary glands untrasounds
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generate the multiple imputed data sets are age, sex,
NAS scores of DPF, ESSDAI, ESSPRI, salivary flow rate,
and Schirmer test score. For comparison with the base-
line, a repeated measures data analysis of variance
(ANOVA) or Wilcoxon signed rank test will be used for
continuous data, whereas Chi-square test or Fisher exact
test will be used for categorical data. In terms of com-
parison between the two groups, Chi-square test or
Fisher exact test will be used for primary outcomes. For
secondary outcomes, the analysis of covariance
(ANCOVA) will be used if the residual are normal dis-
tributed, otherwise Wilcoxon rank sum test will be ap-
plied. To access the success of blinding, the proportion
of subjects who are successfully blinded will be com-
pared by Chi-square test or Fisher exact test. And non-
parametric test will be used to analyze satisfaction. P
<0.05 with two-tailed test indicates statistical
significance.
Discussion
This trial is designed to assess the effects of acupuncture
on DPF of pSS, with the alleviation of the symptoms as
a clinical priority when severe complications absent in
most cases. In this study, we will evaluate if the effect of
acupuncture is not worse than that of sham; the charac-
teristics of the patients who have better responses to
acupuncture at the reasonable end points in multiple
perspectives, covering the subjectivity and objectivity of
patients’ feedback. The objective feedbacks are the struc-
ture and function of salivary glands, the disease activity,
and complications of pSS. The subjective feedbacks in-
clude feelings of DPF and emotions.
Pragmatic inclusion criteria
Inclusion criteria were held pragmatically to facilitate
screening and recruitment. The symptom duration is set
to be “less than 5 years” in the inclusion criteria, because
the structure and function of the glands would be aggra-
vated with the course of disease, which would be more
difficult to be reversed [25] if it’s over 5 years. To make
this trial more similar to the real world where it’s fairly
common for hospitals to accept patients while they are
talking other medicine, we therefore recruit those taking
medicines. However on the other hand, to maintain the
interference from taken medicines during this study as
low as possible, we have a very strict recruitment criteria
listed earlier in this article in case the medicines influ-
ence the results of the study.
Sham needle as a control procedure
With a blunt end and achieving no skin penetration, the
sham needle that we choose as a control procedure in
this trial has the same appearance and gives a likely
sense of penetration to a real one (Fig. 1). In a crossover
study [12], needle penetration was felt by 88.3–100% of
volunteers receiving this kind of sham acupuncture
which are not penetrating in fact, while by 95–98.3% of
volunteers receiving real acupuncture penetrating. The
results make it probable to keep the subjects unaware of
penetration status. To make the end of the needles invis-
ible to subjects when conducting intervention, which
makes subjects to feel the seeming penetration without
knowing if the needles really penetrates through the skin
or not, we will place sticky plastic pads on the acupoints
and then we perform real/sham needles through the
pads and then either penetrating through skin or not de-
pends on which assignment the subjects are in. In result,
subjects will be blinded from their assignments and
would have the same psychological expectations from
the interventions.
Informing strategy
Since many of the subjects in China may have basic
ideas of acupuncture, they would notice the difference
between the needles used in this trial with plastic pads
and the traditional ones applied clinically without (Fig. 2).
Thus, we will inform subjects of the words “a new
method of acupuncture”. “New” refers to the pads we
put on acupoints before we stick needles and that’s for
explaining to subjects in case the differences concern
them. With obedience to the ethics principle, we will
also mention that we are going to assign them into deep
penetrating group and shallow penetrating group based
on the “new method of acupuncture”. This expression
can avoid telling pseudo or sham. If not doing so it may
induce a higher psychological expectation in patients of
study group, which can be beneficial to the study group’s
result. To keep this particular bias out, we inform sub-
jects of “a new method of acupuncture”, meanwhile,
obeying ethic requirements.
Efforts to minimize some other bias
Besides the details of sham needles and the inform strat-
egy, there are a lot of other efforts we take to minimize
the possible bias. We will give subjects acupuncture in
one room and interview them in another, so that the
physicians, the interviewer, the data collectors, and the
statistics will be blind to the group allocations. What
else, to ensure the consistency of manipulation in re-
peated courses of real/sham acupuncture, we will train
the acupuncturist and write a standard operation pro-
cedure (SOP) and this acupuncturist will stick to SOP
throughout the whole study. It is designed to be based
on a specialists’ consensus, which is 3 times of acupunc-
ture a week in the first 4 weeks followed by twice a week
in the second 4 weeks. It obeys the acting rules of this
traditional therapy. And the subjects will be followed up
by another 16 weeks besides 8 weeks of acupuncture, in
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order to ensure the relatively long-term effects to be ob-
served rather than only the short-term ones.
When NAS scores are collected in CRF, a general pSS
condition of the last 24 h will be asked to avoid tempor-
ary diverse interferences only existing during the inter-
views, such as mental relaxation in weekend, weather
changing, and unexpected events in life, etc. Schirmer
test, unstimulated salivary flow, and salivary grand ultra-
sound will be performed by the same technicians to
maintain the consistency, before and after the 8-week
intervention and during the follow-up, which also re-
duces bias.
The selected acupoints
We selected acupoints based on the experiences of Pro-
fessor Lu Zhizheng. The given acupoints will be a prac-
tical option for both domestic and international doctors
and researchers for either their clinical prescriptions or
studies. According to TCM theory, Taiyang (EX-HN5),
Cuanzhu (BL2), and Sizhukong (SJ23) are functioning in
the eye disorders. Chengjiang (RN24), Lianquan (RN23)
and Jiache (ST6) take actions on dry mouth. Waiguan
(SJ5) and Zhaohai (KI6), as the points in the correspond-
ing meridians distal to the local areas, act not only on
dryness of eyes and month, but also on pain and fatigue.
Thus, with these acupoints mentioned above, this study
is designed to evaluate the effect of acupuncture on
symptoms of pSS patients since the acupoints work well
in coordination theoretically and seemingly clinically.
Limitations
Limitations include the restricted sample size and single
centre. Although the study takes place in GAM hospital in
Beijing, it is not possible to limit subjects into only local cit-
izens as there is a large number of people immigrating to
Beijing from all over China and so do the patients. Thus,
the differences of people in different areas of China may
interfere the outcomes of the trial. Although we only accept
subjects having less than 5-year of symptomatic pSS, differ-
ent durations of having it may also interfere the outcomes.
Besides, we can’t eliminate the medicine interferences from
those who are taking other medicines during the study. We
don’t know what the informing strategy would actually and
exactly bring to subjects mentally by telling them we are
researching on a “new” method of acupuncture, although
our initial purpose of doing so is to make subjects to have
the same expectations from their interventions. Another
limitation is that the acupuncturist knows assignments and
he conducts, in which case the communication between
the acupuncturist and subjects may, more or less, change
the expectations of subjects, which would cause bias.
What’s more, the acupoints studied in this trial are con-
stant. It is not the way of applying acupuncture clinically in
TCM way, in which case we wouldn’t know how
acupuncture would act if it’s done with Differentiation
Method, a way of diagnosis in TCM, which also directs
treatments. Finally, if there is a third group by standard
care, the result would be more convincing; while, standard
treatments based on the guideline of pSS had not been
established yet before the start of this study, and our fund is
not financially supportive to set a third group of cohort.
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recruitment started in March 2016. It is anticipated to take 24 months to
finish recruiting all the subjects and data collection. Data analysis is expected
to be finished a month after data collection, followed by a submission to
peer-reviewed journal.
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